Table 2.
Anti-SARS-CoV-2 IgG titer after BNT162b2 primovaccination and booster vaccination according to history of COVID-19, sex and age.
| Anti-SARS-CoV-2 IgG AU/mL Median (IQR) |
Correlation Analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Time Point | Pre-Vaccination COVID-19 | Sex | Age | |||||
| Yes (N = 45) | No (N = 364) | p | Male (N = 73) | Female (N = 332) | p | r | p | |
| Three weeks after FVD * (N = 388) |
13,460.0 (7730.0–22,167.0) |
832.4 (400.0–1560.1) |
<0.001 | 907.4 (461.2–2390.2) |
965.5 (461.2–2390.2) |
0.284 | −0.42 | <0.001 |
| One month after SVD * (N = 375) |
11,085.0 (8380.0–19,718.0) |
9997.1 (5024.7–17,318.4) |
0.065 | 8054.0 (3850.0–18,979.0) |
10,416.4 (5786.5–17,415.7) |
0.132 | −0.19 | 0.006 |
| Three months after SVD (N = 353) |
4049.0 (2524.0–6018.0) |
3004.9 (1672.0–4652.1) |
0.007 | 2823.7 (1330.2–4878.6) |
3176.2 (1878.5–4827.8) |
0.398 | −0.20 | 0.005 |
| Six months after SVD (N = 353) |
1443.9 (1006.8–3416.0) |
1000.8 (587.9–1493.9) |
<0.001 | 936.5 (504.8–1650.2) |
1058.0 (655.6–1547.2) |
0.532 | −0.22 | 0.004 |
| Nine months after SVD (N = 370) |
1067.7 (583.3–2425.4) |
556.0 (336.5–878.4) |
<0.001 | 598.0 (361.8–1026.8) |
578.1 (361.8–1026.8) |
0.912 | −0.23 | 0.003 |
| One week after BD * (N = 323) |
21,094.0 (16,772.0–35,419.0) |
28,887.0 (18,072.0–48,255.0) |
0.072 | 30,627.0 (13,856.0–44,039.0) |
27,868.0 (17,747.0–45,866.0) |
0.671 | −0.11 | 0.080 |
| One month after BD (N = 279) |
18,959.0 (11,437.0–27,895.0) |
26,232.0 (16,631.0–39,262.0) |
0.094 | 24,469.0 (17,215.0–35,537.0) |
25,734.0 (15,329.0–39,147.0) |
0.714 | 0.14 | 0.061 |
| Three months after BD (N = 209) |
10,832.0 (5492.0–23,757.0) |
12,569.0 (8008.0–20,779.0) |
0.292 | 12,842.0 (8102.0–24,705.0) |
12,406.0 (7562.0–20,845.0) |
0.644 | 0.19 | 0.064 |
| Six months after BD (N = 139) |
4356.0 (2716.0–8386.0) |
5609.9 (3603.1–12,056.4) |
0.321 | 6887.0 (4354.0–13,903.0) |
5040.2 (3257.2–10,960.3) |
0.194 | 0.13 | 0.052 |
* FVD = first vaccine dose, SVD = second vaccine dose, BD = booster dose, IQR = interquartile range, # r = Spearman correlation coefficient. Sera from participants after COVID-19 diagnosis were not included. p-values were corrected for multiple testing with the Bonferroni method.